Abstract
Active immunization is the only reliable means of preventing TBE. Evidence suggests that effectiveness is greater than 95%. Breakthrough infections in fully immunized individuals, however, do occur. Recent data indicate that the duration of protection following basic immunization is substantially longer than previously appreciated. The vast majority of vaccinees are still seropositive > or = 8 years after the last dose. Thus, the current practice of administering booster doses every 3 years is a topic of intense debate. Until it is resolved, patients can be offered the determination of a serum anti-TBE IgG titre as an alternative to "blind" administration of a booster dose. It has recently been shown that seropositivity determined by some commonly used commercial ELISA tests correlates closely with the presence of protective antibody. In Switzerland, TBE vaccination is currently recommended for individuals older than 6 years of age who frequently dwell in endemic areas. Since 2005, health care insurances are required to cover for costs incurred by immunization according to these recommendations.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
